MeSH term
Frequency | Condition_Probility | Animals | 26 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Genetic Vectors | 4 | 0.0 |
Hamsters | 2 | 0.0 |
Hela Cells | 5 | 0.0 |
Humans | 60 | 0.0 |
Proteins/metabolism | 4 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 44 | 0.0 |
Transfection | 11 | 0.0 |
Apoptosis/*physiology | 8 | 1.0 |
Caspases/physiology | 2 | 3.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
Rats | 8 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
*Apoptosis | 14 | 0.0 |
Blotting, Western | 9 | 0.0 |
Carrier Proteins/metabolism | 6 | 0.0 |
Cell Line | 9 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Cell Survival | 3 | 0.0 |
Cytochromes c/metabolism | 3 | 4.0 |
Cytosol/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Down-Regulation | 3 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Membrane Potentials | 2 | 0.0 |
Mitochondria/metabolism | 3 | 1.0 |
Mitochondrial Proteins/metabolism | 3 | 15.0 |
Models, Biological | 3 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 5 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 6 | 1.0 |
Reactive Oxygen Species | 2 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 23 | 0.0 |
Mice | 16 | 0.0 |
Antigens, CD95/*physiology | 6 | 7.0 |
Male | 9 | 0.0 |
Mitochondria/*physiology | 3 | 5.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Caspases/metabolism | 15 | 2.0 |
Female | 10 | 0.0 |
Ligands | 3 | 0.0 |
Mitochondria/*metabolism | 3 | 1.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Antigens, CD95/metabolism | 3 | 2.0 |
Apoptosis/*drug effects | 13 | 1.0 |
Carrier Proteins | 2 | 3.0 |
Caspases/antagonists & inhibitors/metabolism | 4 | 4.0 |
Combined Modality Therapy | 3 | 0.0 |
Cytochrome c Group/metabolism | 9 | 6.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Carrier Proteins/genetics/*metabolism | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Jurkat Cells | 5 | 0.0 |
Time Factors | 7 | 0.0 |
Apoptosis | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/chemistry/metabolism | 3 | 37.0 |
Tyrosine 3-Monooxygenase/metabolism | 2 | 1.0 |
Drug Synergism | 3 | 0.0 |
Histone Deacetylases/*antagonists & inhibitors | 2 | 4.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Hepatocytes/drug effects | 2 | 16.0 |
Mutation | 2 | 0.0 |
Permeability | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 3 | 2.0 |
Caspases/*metabolism | 6 | 2.0 |
Comparative Study | 4 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
DNA Fragmentation | 3 | 0.0 |
Membrane Glycoproteins/physiology | 2 | 1.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Mitochondria/physiology | 4 | 6.0 |
Amino Acid Sequence | 6 | 0.0 |
Hydrophobicity | 2 | 2.0 |
Molecular Sequence Data | 8 | 0.0 |
Adenoviridae/genetics | 2 | 0.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Oligopeptides/pharmacology | 4 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Middle Aged | 4 | 0.0 |
Cell Death | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 5 | 1.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Binding Sites | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 2 | 0.0 |
Viral Proteins/*metabolism | 2 | 3.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Adult | 3 | 0.0 |
Aged | 3 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Caspases/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism/pharmacology | 2 | 4.0 |
Models, Molecular | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Pregnancy | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 2 | 2.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Adolescent | 2 | 0.0 |
Child | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Apoptosis/genetics/*physiology | 2 | 5.0 |
Apoptosis/*genetics | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism | 3 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 3 | 1.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Cytochrome c Group/secretion | 2 | 14.0 |
